Recce Ltd has released a press release.
Correction to Appendix 4C and Quarterly Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Australia Patent Granted for RECCE Anti-Infectives
- AUD $6.75m R&D Rebate Approved
- Ethics Approval for Registrational Ph3 R327G Clinical Trial
Later from Recce Pharmaceuticals
- Pause in Trading
- Trading Halt
- Positive Phase II Data from Clinical Trial of R327 Gel
- Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
- Japan Patent Allowance for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals